Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes

Internal Medicine Journal
A PhilpottJohn D Horowitz

Abstract

Perhexiline is a prophylactic anti-anginal agent that ameliorates the metabolic basis for myocardial ischaemia and is increasingly used in the management of acute coronary syndromes. No intravenous preparation is available and usual oral loading regimens require 2-3 days to achieve therapeutic drug levels. Two patients presenting to hospital with single-dose over-dosage of perhexiline (6500 mg and 1000 mg, respectively) provided a basis for examining the safety of large single dosage of perhexiline and associated time-course of drug levels. Neither patient had previously taken perhexiline. Peak plasma perhexiline concentrations occurred within 12 h of ingestion and were 2.58 and 0.50 mg/L, respectively (therapeutic range 0.15-0.60 mg/L). The first patient developed transient nausea and vomiting; the second patient had no adverse effects. Subsequently, a series of 10 patients with acute coronary syndromes received an 800-mg loading dose. Peak concentrations occurred within 12 h postdose; the mean levels achieved were 0.40 +/- 0.16 mg/L (standard error of the mean). No serious adverse effects were seen. Two patients reported transient nausea or vomiting within 24 h of the loading dose. The utility of this rapid loading regimen fo...Continue Reading

References

Feb 28, 1976·The Medical Journal of Australia·M J BrownM L Mashford
Dec 1, 1990·Australian and New Zealand Journal of Medicine·G D Kerr, G Ingham
Nov 1, 1986·International Journal of Cardiology·J D HorowitzW J Louis
Mar 1, 1981·Journal of Pharmaceutical Sciences·J D HorowitzW J Louis
Jan 1, 1997·Advances in Pharmacology·F P Guengerich
Jan 22, 2002·Therapeutic Drug Monitoring·R HusseinR L Rasiah
Mar 20, 2002·Advances in Experimental Medicine and Biology·K MalmbergUNKNOWN DIGAAMI study

❮ Previous
Next ❯

Citations

Apr 21, 2007·Cardiovascular Drug Reviews·Houman AshrafianMichael P Frenneaux
Sep 18, 2015·European Journal of Clinical Pharmacology·Cher-Rin ChongBenedetta C Sallustio
Aug 31, 2020·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Zhen RenLei Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.